UK biopharmaceutical manufacturing boost
The UK government has awarded a prestigious grant to a biotech consortium led by consultants BioPharm Services, and supported by Avecia and Cambridge Antibody Technology. The three-year project will develop a knowledge management model to help biopharmaceutical manufacturers bring new products from development to manufacture by ensuring consistency, speeding development and reducing errors. The model optimizes manufacturing processes by identifying cost-effective options that minimize capital investment and maximize asset utilization. Project leader Andrew Sinclair of BioPharm said: "Product development in this industry can take anything up to nine years. We are aware that many biopharmaceutical manufacturers are failing to capitalize on the benefits of experience gained both across and within projects. Currently data on process, manufacturing, plant performance and costs all exist in isolation. We want to link those datasets to create a powerful, integrated decision support tool. We're developing a knowledge database and the software platform that will allow scientists, engineers, business managers and marketing people to access and use the data to support business, manufacturing protocols, validation documentation, product data and all the other documentation needed to bring a product to market."
www.biopharmservices.com
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.